
Michael R Jaff

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4202125/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2011, 123, 1788-1830.	1.6	1,842
2	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. JACC: Cardiovascular Interventions, 2015, 8, 1382-1392.	1.1	648
3	American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Advances, 2020, 4, 4693-4738.	2.5	636
4	Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage. JAMA - Journal of the American Medical Association, 2014, 311, 2414.	3.8	602
5	Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. New England Journal of Medicine, 2017, 377, 2240-2252.	13.9	557
6	Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. New England Journal of Medicine, 2016, 374, 1011-1020.	13.9	486
7	Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. Circulation, 2016, 133, 1472-1483.	1.6	426
8	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation, 2018, 137, 961-972.	1.6	368
9	Durability of Treatment Effect Using a Drug-Coated Balloon for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2015, 66, 2329-2338.	1.2	325
10	Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions. Journal of the American College of Cardiology, 2013, 61, 2417-2427.	1.2	307
11	Evaluation and Treatment of Patients With Lower Extremity Peripheral ArteryÂDisease. Journal of the American College of Cardiology, 2015, 65, 931-941.	1.2	269
12	Supervised Exercise, Stent Revascularization, or MedicalÂTherapy forÂClaudication Due to Aortoiliac Peripheral Artery Disease. Journal of the American College of Cardiology, 2015, 65, 999-1009.	1.2	225
13	2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Journal of the American College of Cardiology, 2018, 71, 1021-1034.	1.2	211
14	Lower Extremity Revascularization Using Directional Atherectomy. JACC: Cardiovascular Interventions, 2014, 7, 923-933.	1.1	210
15	A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet, The, 2018, 392, 1541-1551.	6.3	196
16	Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis. Circulation, 2019, 139, 1162-1173.	1.6	196
17	A Multidisciplinary Pulmonary Embolism Response Team. Chest, 2016, 150, 384-393.	0.4	195
18	Safety and Effectiveness of Stent Placement for Iliofemoral Venous Outflow Obstruction. Circulation: Cardiovascular Interventions, 2015, 8, e002772.	1.4	186

#	Article	IF	CITATIONS
19	Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	180
20	Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices. JAMA Cardiology, 2019, 4, 332.	3.0	178
21	Dissection and Aneurysm in Patients WithÂFibromuscular Dysplasia. Journal of the American College of Cardiology, 2016, 68, 176-185.	1.2	168
22	Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST LI) Trial. Journal of the American Heart Association, 2016, 5, .	1.6	158
23	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries. Journal of Endovascular Therapy, 2015, 22, 663-677.	0.8	152
24	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Vascular Medicine, 2015, 20, 465-478.	0.8	127
25	Critical Limb Ischemia. Journal of the American College of Cardiology, 2016, 68, 2002-2015.	1.2	127
26	Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	126
27	Imaging of the carotid arteries: the role of duplex ultrasonography, magnetic resonance arteriography, and computerized tomographic arteriography. Vascular Medicine, 2008, 13, 281-292.	0.8	124
28	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Annals of Vascular Diseases, 2015, 8, 343-357.	0.2	122
29	Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention. Journal of the American College of Cardiology, 2017, 69, 2266-2275.	1.2	122
30	SCAI consensus guidelines for device selection in femoralâ€popliteal arterial interventions. Catheterization and Cardiovascular Interventions, 2018, 92, 124-140.	0.7	122
31	Mortality and Paclitaxel-Coated Devices. Circulation, 2020, 141, 1859-1869.	1.6	122
32	Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circulation: Cardiovascular Interventions, 2019, 12, e007702.	1.4	120
33	The Systolic Blood Pressure Difference Between Arms and Cardiovascular Disease in the Framingham Heart Study. American Journal of Medicine, 2014, 127, 209-215.	0.6	112
34	Thrombectomy using suction filtration and venoâ€venous bypass: Single center experience with a novel device. Catheterization and Cardiovascular Interventions, 2015, 86, E81-7.	0.7	109
35	Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart, 2014, 1, e000117.	0.9	103
36	Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. Journal of Thrombosis and Thrombolysis, 2019, 47, 31-40.	1.0	94

#	Article	IF	CITATIONS
37	SUPERB final 3â€year outcomes using interwoven nitinol biomimetic supera stent. Catheterization and Cardiovascular Interventions, 2017, 89, 1259-1267.	0.7	92
38	Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: Results from the HERCULES trial. Catheterization and Cardiovascular Interventions, 2012, 80, 343-350.	0.7	87
39	Clinical Manifestations of Fibromuscular Dysplasia Vary by Patient Sex. Journal of the American College of Cardiology, 2013, 62, 2026-2028.	1.2	80
40	Contemporary Management and Outcomes of Patients with Massive and Submassive Pulmonary Embolism. American Journal of Medicine, 2018, 131, 1506-1514.e0.	0.6	79
41	Percutaneous Therapies for Peripheral Artery Disease. Circulation, 2016, 134, 2008-2027.	1.6	78
42	An update on methods for revascularization and expansion of the TASC lesion classification to include belowâ€theâ€knee arteries: A supplement to the interâ€society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee*. Catheterization and Cardiovascular Interventions, 2015, 86, 611-625.	0.7	76
43	Clinical Outcomes and Medical Care Costs Among Medicare Beneficiaries Receiving Therapy for Peripheral Arterial Disease. Annals of Vascular Surgery, 2010, 24, 577-587.	0.4	73
44	SCAI appropriate use criteria for peripheral arterial interventions: An update. Catheterization and Cardiovascular Interventions, 2017, 90, E90-E110.	0.7	69
45	Outcomes After Carotid Artery Stenting in Medicare Beneficiaries, 2005 to 2009. JAMA Neurology, 2015, 72, 276.	4.5	66
46	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 2113-2123.	1.1	60
47	S.M.A.R.T. Self-Expanding Nitinol Stent for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (STROLL): 1-Year Outcomes. Journal of Vascular and Interventional Radiology, 2015, 26, 21-28.	0.2	59
48	Mortality Assessment of Paclitaxel-Coated Balloons. Circulation, 2019, 140, 1145-1155.	1.6	59
49	Ultrasound-facilitated, catheter-directed thrombolysis vs anticoagulation alone for acute intermediate-high-risk pulmonary embolism: Rationale and design of the HI-PEITHO study. American Heart Journal, 2022, 251, 43-53.	1.2	59
50	Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2020, 8, 8-23.e18.	0.9	55
51	Prevalence of Intracranial Aneurysm in Women With Fibromuscular Dysplasia. JAMA Neurology, 2017, 74, 1081.	4.5	54
52	Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon. JACC: Cardiovascular Interventions, 2018, 11, 2357-2364.	1.1	52
53	Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease. Circulation: Cardiovascular Interventions, 2018, 11, e005654.	1.4	51
54	Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated BalloonsÂVersus Standard Percutaneous Transluminal Angioplasty. JACC: Cardiovascular Interventions, 2016, 9, 2343-2352.	1.1	50

#	Article	IF	CITATIONS
55	One-Year Outcomes Following Directional Atherectomy of Infrapopliteal Artery Lesions. Journal of Endovascular Therapy, 2015, 22, 839-846.	0.8	48
56	Cardiopulmonary Exercise Testing in Patients Following Massive and Submassive Pulmonary Embolism. Journal of the American Heart Association, 2018, 7, .	1.6	48
57	A single stent strategy in patients with lifestyle limiting claudication: 3â€year results from the Durability II trial. Catheterization and Cardiovascular Interventions, 2015, 86, 164-170.	0.7	47
58	Paclitaxel-Coated Zilver PTX Drug-Eluting Stent Treatment Does Not Result in Increased Long-Term All-Cause Mortality Compared to Uncoated Devices. CardioVascular and Interventional Radiology, 2020, 43, 8-19.	0.9	47
59	Vascular Health in Kawasaki Disease. Journal of the American College of Cardiology, 2013, 62, 1114-1121.	1.2	46
60	Human type I pancreatic elastase treatment of arteriovenous fistulas in patients with chronic kidney disease. Journal of Vascular Surgery, 2014, 60, 454-461.e1.	0.6	45
61	Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. Vascular Medicine, 2016, 21, 400-407.	0.8	44
62	Proximal Versus Distal Embolic Protection for Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2015, 8, 609-615.	1.1	43
63	Endovascular Interventions for Femoropopliteal Peripheral Artery Disease: A Network Meta-Analysis of Current Technologies. Journal of Vascular and Interventional Radiology, 2017, 28, 1617-1627.e1.	0.2	42
64	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Enables the Detection of Recurrent Same-Site Deep Vein Thrombosis by Illuminating Recently Formed, Neutrophil-Rich Thrombus. Circulation, 2014, 130, 1044-1052.	1.6	40
65	Stellarex drugâ€coated balloon for treatment of femoropopliteal arterial disease—The <scp>ILLUMENATE</scp> Clobal Study: 12â€Month results from a prospective, multicenter, singleâ€arm study. Catheterization and Cardiovascular Interventions, 2018, 91, 497-504.	0.7	40
66	Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute pulmonary embolism: A multicenter comparison of patient-centered outcomes. Vascular Medicine, 2019, 24, 241-247.	0.8	39
67	Drugâ€coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2â€year results of the MDTâ€2113 SFA Japan randomized trial. Catheterization and Cardiovascular Interventions, 2019, 93, 664-672.	0.7	39
68	Drug-Coated Balloon Treatment forÂFemoropopliteal Artery Disease. JACC: Cardiovascular Interventions, 2019, 12, 484-493.	1.1	37
69	Inferior Vena Cava Filter Usage, Complications, and Retrieval Rate in Cancer Patients. American Journal of Medicine, 2014, 127, 1111-1117.	0.6	35
70	Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial. Vascular Medicine, 2019, 24, 442-451.	0.8	35
71	One-Year Results of the LIBERTY 360 Study: Evaluation of Acute and Midterm Clinical Outcomes of Peripheral Endovascular Device Interventions. Journal of Endovascular Therapy, 2019, 26, 143-154.	0.8	35
72	High utilization rate of vena cava filters in deep vein thrombosis. Thrombosis and Haemostasis, 2005, 93, 1117-1119.	1.8	34

#	Article	IF	CITATIONS
73	Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort. Journal of Endovascular Therapy, 2020, 27, 693-705.	0.8	34
74	Anti-Chlamydial Antibiotic Therapy for Symptom Improvement in Peripheral Artery Disease. Circulation, 2009, 119, 452-458.	1.6	32
75	Vascular Teams in PeripheralÂVascularÂDisease. Journal of the American College of Cardiology, 2019, 73, 2477-2486.	1.2	32
76	The impact of prolonged lower limb ischemia on amputation, mortality, and functional status: The FRIENDS registry. American Heart Journal, 2014, 168, 577-587.	1.2	31
77	Bioresorbable Everolimus-Eluting VascularÂScaffold for Patients With PeripheralÂArtery Disease (ESPRIT I). JACC: Cardiovascular Interventions, 2016, 9, 1178-1187.	1.1	30
78	Effect of Delayed Inferior Vena Cava Filter Retrieval After Early Initiation of Anticoagulation. American Journal of Cardiology, 2014, 113, 389-394.	0.7	28
79	Asynchronous vascular consultation via electronic methods: A feasibility pilot. Vascular Medicine, 2015, 20, 551-556.	0.8	27
80	Anti-platelet and anti-hypertension medication use in patients with fibromuscular dysplasia: Results from the United States Registry for Fibromuscular Dysplasia. Vascular Medicine, 2015, 20, 447-453.	0.8	26
81	Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. Journal of Vascular and Interventional Radiology, 2016, 27, 787-794.	0.2	26
82	<scp>SCAI/SVM</scp> expert consensus statement on Carotid Stenting: Training and credentialing for Carotid Stenting. Catheterization and Cardiovascular Interventions, 2016, 87, 188-199.	0.7	25
83	Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: Two eras at an urban tertiary care hospital. Vascular Medicine, 2018, 23, 60-64.	0.8	25
84	Dissections After Infrainguinal Percutaneous Transluminal Angioplasty: A Systematic Review and Current State of Clinical Evidence. Journal of Endovascular Therapy, 2019, 26, 479-489.	0.8	25
85	Comparative Effectiveness of Carotid Artery Stenting Versus Carotid Endarterectomy Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 275-285.	0.9	24
86	Cerebrovascular fibromuscular dysplasia. Neurology: Clinical Practice, 2017, 7, 225-236.	0.8	24
87	Paclitaxel and Mortality: The Dose Argument Is Critical. Journal of Endovascular Therapy, 2019, 26, 467-470.	0.8	24
88	Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial. Journal of Endovascular Therapy, 2018, 25, 68-78.	0.8	23
89	Outcomes of catheter-directed versus systemic thrombolysis for the treatment of pulmonary embolism: A real-world analysis of national administrative claims. Vascular Medicine, 2020, 25, 334-340.	0.8	23
90	Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study. Theranostics, 2015, 5, 1317-1327.	4.6	21

#	Article	IF	CITATIONS
91	One-year outcomes of the U.S. and Japanese regulatory trial of the Misago stent for treatment of superficial femoral artery disease (OSPREY study). Journal of Vascular Surgery, 2016, 63, 370-376.e1.	0.6	21
92	Impact of Pulmonary Arterial Clot Location on Pulmonary Embolism Treatment and Outcomes (90ÂDays). American Journal of Cardiology, 2017, 119, 802-807.	0.7	21
93	One-Year Outcomes Following Directional Atherectomy of Popliteal Artery Lesions: Subgroup Analysis of the Prospective, Multicenter DEFINITIVE LE Trial. Journal of Endovascular Therapy, 2018, 25, 100-108.	0.8	21
94	Drug-Coated Balloon Treatment of Femoropopliteal Lesions Typically Excluded From Clinical Trials: 12-Month Findings From the IN.PACT Global Study. Journal of Endovascular Therapy, 2018, 25, 673-682.	0.8	21
95	<scp>SCAI</scp> guidelines on device selection in <scp>Aortoâ€liac</scp> arterial interventions. Catheterization and Cardiovascular Interventions, 2020, 96, 915-929.	0.7	21
96	Time-Restricted Salutary Effects of Blood Flow Restoration on Venous Thrombosis and Vein Wall Injury in Mouse and Human Subjects. Circulation, 2021, 143, 1224-1238.	1.6	21
97	A Comparison of Clinical Outcomes for Diabetic and Nondiabetic Patients Following Directional Atherectomy in the DEFINITIVE LE Claudicant Cohort. Journal of Endovascular Therapy, 2015, 22, 701-711.	0.8	20
98	The LIBERTY study: Design of a prospective, observational, multicenter trial to evaluate the acute and long-term clinical and economic outcomes of real-world endovascular device interventions in treating peripheral artery disease. American Heart Journal, 2016, 174, 14-21.	1.2	20
99	Patientâ€level metaâ€analysis of 999 claudicants undergoing primary femoropopliteal nitinol stent implantation. Catheterization and Cardiovascular Interventions, 2017, 89, 1250-1256.	0.7	20
100	Relationship Between Physician and Hospital Procedure Volume and Mortality After Carotid Artery Stenting Among Medicare Beneficiaries. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S81-9.	0.9	19
101	Treatment of submassive and massive pulmonary embolism: a clinical practice survey from the second annual meeting of the Pulmonary Embolism Response Team Consortium. Journal of Thrombosis and Thrombolysis, 2018, 46, 39-49.	1.0	19
102	Adventitial Drug Delivery of Dexamethasone to Improve Primary Patency in the Treatment of Superficial Femoral and Popliteal Artery Disease. JACC: Cardiovascular Interventions, 2018, 11, 921-931.	1.1	18
103	Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits. JACC Basic To Translational Science, 2020, 5, 685-695.	1.9	18
104	Cost-Effectiveness of Pharmacomechanical Catheter-Directed Thrombolysis Versus Standard Anticoagulation in Patients With Proximal Deep Vein Thrombosis. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005659.	0.9	17
105	Drug-coated balloons to improve femoropopliteal artery patency: Rationale and design of the LEVANT 2 trial. American Heart Journal, 2015, 169, 479-485.	1.2	16
106	Longâ€ŧerm clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: 3â€year results from the STROLL study. Catheterization and Cardiovascular Interventions, 2018, 92, 106-114.	0.7	16
107	Propensity Score–Adjusted Comparison of Long-Term Outcomes Among Revascularization Strategies for Critical Limb Ischemia. Circulation: Cardiovascular Interventions, 2019, 12, e008097.	1.4	16
108	Strength of Evidence Underlying the American Heart Association/American College of Cardiology Guidelines on Endovascular and Surgical Treatment of Peripheral Vascular Disease:. Circulation: Cardiovascular Interventions, 2019, 12, e007244.	1.4	16

#	Article	IF	CITATIONS
109	Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty. Journal of Endovascular Therapy, 2020, 27, 946-955.	0.8	16
110	A Comparison of Patients Diagnosed With Pulmonary Embolism Who Are ≥65ÂYears With Patients <65ÂYears. American Journal of Cardiology, 2015, 115, 681-686.	0.7	15
111	Stent placement in the superficial femoral and proximal popliteal arteries with the innova selfâ€expanding bare metal stent system. Catheterization and Cardiovascular Interventions, 2017, 89, 1069-1077.	0.7	15
112	Thrombolytics for venous thromboembolic events: a systematic review with meta-analysis. Blood Advances, 2020, 4, 1539-1553.	2.5	15
113	Carotid Artery Intima-Media Thickness Measurements in the Youth: Reproducibility and Technical Considerations. Journal of the American Society of Echocardiography, 2015, 28, 309-316.	1.2	14
114	Endovascular Intervention for the Treatment of Trans-Atlantic Inter-Society Consensus (TASC) D Femoropopliteal Lesions: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine, 2021, 22, 52-65.	0.3	14
115	Accreditation status and geographic location of outpatient vascular testing facilities among Medicare beneficiaries: The VALUE (Vascular Accreditation, Location & Utilization Evaluation) Study. Vascular Medicine, 2014, 19, 376-384.	0.8	13
116	Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries. International Angiology, 2017, 36, 203-215.	0.4	13
117	iCAST Balloon-Expandable Covered Stent for Iliac Artery Lesions: 3-Year Results from the iCARUS Multicenter Study. Journal of Vascular and Interventional Radiology, 2019, 30, 822-829.e4.	0.2	13
118	Balloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter Study. Journal of Vascular and Interventional Radiology, 2019, 30, 836-844.e1.	0.2	13
119	Two-year Clinical Evaluation of the Zilver Vascular Stent for Symptomatic Iliac Artery Disease. Journal of Vascular and Interventional Radiology, 2010, 21, 1489-1494.	0.2	12
120	Anticoagulation Is Associated with Decreased Inferior Vena Cava Filter-Related Complications in Patients with Metastatic Carcinoma. American Journal of Medicine, 2017, 130, 77-82.e1.	0.6	12
121	Response by Schneider et al to Letter Regarding Article, "Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trialâ€: Circulation: Cardiovascular Interventions, 2018, 11, e006699.	1.4	12
122	Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts. Journal of Vascular Surgery, 2019, 70, 1177-1191.e9.	0.6	12
123	SCAI publications committee manual of standard operating procedures. Catheterization and Cardiovascular Interventions, 2020, 96, 145-155.	0.7	12
124	Core content for training in venous and lymphatic medicine. Phlebology, 2014, 29, 587-593.	0.6	11
125	Key Concepts in Critical Limb Ischemia: Selected Proceedings from the 2015 Vascular Interventional Advances Meeting. Annals of Vascular Surgery, 2017, 38, 191-205.	0.4	11
126	Carotid Stent Fractures Are Not Associated With Adverse Events. Circulation, 2018, 137, 49-56.	1.6	11

#	Article	IF	CITATIONS
127	Intersocietal Accreditation Commission Accreditation Status of Outpatient Cerebrovascular Testing Facilities Among Medicare Beneficiaries. Journal of Ultrasound in Medicine, 2016, 35, 1957-1965.	0.8	10
128	Peripheral vascular manifestation in patients receiving an amphetamine analog: A case series. Vascular Medicine, 2019, 24, 50-55.	0.8	10
129	Expanding opportunities to understand quality and outcomes of peripheral vascular interventions: The ACC NCDR PVI Registry. American Heart Journal, 2019, 216, 74-81.	1.2	10
130	Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain. Circulation: Cardiovascular Interventions, 2019, 12, e007730.	1.4	10
131	Digital Subtraction Angiography Prior to an Amputation for Critical Limb Ischemia (CLI): An Expert Recommendation Statement From the CLI Global Society to Optimize Limb Salvage. Journal of Endovascular Therapy, 2020, 27, 540-546.	0.8	9
132	Clinical Impact of Contralateral Carotid Occlusion in Patients Undergoing Carotid Artery Revascularization. Journal of the American College of Cardiology, 2021, 77, 835-844.	1.2	9
133	The first 10 years of the American Board of Vascular Medicine. Vascular Medicine, 2015, 20, 69-73.	0.8	8
134	Case 13-2016. New England Journal of Medicine, 2016, 374, 1671-1680.	13.9	8
135	Nitinol Self-Expanding Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Three-Year Results of the RELIABLE Japanese Multicenter Study. Annals of Vascular Diseases, 2018, 11, 324-334.	0.2	8
136	Usefulness of a Computerized Reminder System to Improve Inferior Vena Cava Filter Retrieval and Complications. American Journal of Cardiology, 2019, 123, 348-353.	0.7	8
137	Response to Letter Regarding Article, "The United States Preventive Services Task Force Recommendation Statement on Screening for Peripheral Arterial Disease: More Harm Than Benefit?― Circulation, 2007, 115, .	1.6	7
138	Chronically anticoagulated patients who need surgery: Can lowâ€molecularâ€weight heparins really be used to "bridge―patients instead of intravenous unfractionated heparin?. Catheterization and Cardiovascular Interventions, 2009, 74, S17-21.	0.7	7
139	Vascular specialist response to Medicare Evidence Development Coverage Advisory Committee (MEDCAC) panel on peripheral artery disease of the lower extremities. Vascular Medicine, 2016, 21, 281-286.	0.8	7
140	Comparison of Inferior Vena Cava Filters Placed at the Bedside via Intravenous Ultrasound Guidance Versus Fluoroscopic Guidance. Annals of Vascular Surgery, 2017, 39, 250-255.	0.4	7
141	Public Health Impact of the Centers for Medicare and Medicaid Services Decision on Pass-Through Add-On Payments for Drug-Coated Balloons. JACC: Cardiovascular Interventions, 2018, 11, 496-499.	1.1	7
142	Design Strategies for Global Clinical Trials of Endovascular Devices for Critical Limb Ischemia (CLI) ― A Joint USA-Japanese Perspective ―. Circulation Journal, 2018, 82, 2233-2239.	0.7	7
143	A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease. Journal of Endovascular Therapy, 2017, 24, 499-503.	0.8	6
144	Results From the VISIBILITY Iliac Study: Primary and Cohort Outcomes at 9 Months. Journal of Endovascular Therapy, 2017, 24, 342-348.	0.8	6

#	Article	IF	CITATIONS
145	Imaging the Carotid Bifurcation: Toward Standardization. Seminars in Vascular Surgery, 2008, 21, 73-79.	1.1	5
146	The Society for Vascular Medicine: The first quarter century. Vascular Medicine, 2015, 20, 60-68.	0.8	5
147	A Measured Approach to Vena Cava Filter Use—Respect Rather Than Regret. JAMA Cardiology, 2017, 2, 5.	3.0	5
148	Angiographic classification of patterns of restenosis following femoropopliteal artery intervention: A proposed scoring system. Catheterization and Cardiovascular Interventions, 2017, 90, 639-646.	0.7	5
149	Cost-effectiveness of a paclitaxel-eluting stent (Eluvia) compared to Zilver PTX for endovascular femoropopliteal intervention. Journal of Medical Economics, 2022, 25, 880-887.	1.0	5
150	Nine-Month Outcomes of the DURABILITY Iliac Study on Self-Expanding Stents for Symptomatic Peripheral Artery Disease. Annals of Vascular Surgery, 2018, 51, 37-47.	0.4	4
151	Drug-eluting Balloons: Are These Failed Solutions for the Treatment of Below-the-knee Peripheral Artery Disease?. Annals of Vascular Surgery, 2014, 28, 1078-1079.	0.4	3
152	What's a Doctor to Do? Balloon, Stents, Drugs, Drills, andÂTreadmills. JACC: Cardiovascular Interventions, 2015, 8, 1113-1114.	1.1	3
153	Modern multidisciplinary team approach is crucial in treatment for critical limb threatening ischemia. Journal of Cardiovascular Surgery, 2021, 62, 124-129.	0.3	3
154	The Top 12 Advances in Vascular Medicine. Journal of Endovascular Therapy, 2004, 11, II-21-II-31.	0.8	2
155	Favorable Angiographic Outcome AfterÂTreatment of Infrapopliteal Lesions With Drug-Coated Balloons Without Clinical Benefit. JACC: Cardiovascular Interventions, 2016, 9, 1081-1082.	1.1	2
156	Three-Year Efficacy and Safety of the MisagoÂPeripheral Stent for Superficial Femoral Artery Disease: Final Results from the OSPREY Trial. Journal of Vascular and Interventional Radiology, 2020, 31, 978-985.	0.2	2
157	Non-Invasive Carotid Imaging. Interventional Cardiology Clinics, 2014, 3, 13-20.	0.2	1
158	The Role of Sonographic Imaging to Assess the Pathophysiology of Cording in Patients Treated for Breast Cancer. Journal of Diagnostic Medical Sonography, 2015, 31, 276-281.	0.1	1
159	Vascular Specialist Response to Medicare Evidence Development Coverage Advisory Committee (MEDCAC) Panel on Peripheral Artery Disease of the Lower Extremities. Journal of the American College of Radiology, 2016, 13, 1296-1301.	0.9	1
160	Vascular specialist response to medicare evidence development coverage advisory committee (MEDCAC) panel on peripheral artery disease of the lower extremities. Catheterization and Cardiovascular Interventions, 2016, 87, 1181-1186.	0.7	1
161	The CLOSER trial: a multiâ€center study on the clinical safety and effectiveness of Closer TM VSS, a novel resorbable transfemoral vascular access sealing system. Catheterization and Cardiovascular Interventions, 2017, 90, 798-805.	0.7	1
162	Why Did I Not Think of This? Water Therapy for PAD! (Invited Commentary). Annals of Vascular Surgery, 2018, 49, 7-8.	0.4	1

#	ARTICLE	IF	CITATIONS
163	Response by Weinberg et al to Letter Regarding Article, a€œCarotid Stent Fractures Are Not Associated With Adverse Events: Results From the ACT-1 Multicenter Randomized Trial (Carotid Angioplasty and) Tj ETQq1	1 0.78431 1.6	4 rgBT /Over 1
164	2676-2677. Analysis of Costs and Payments for Inferior Vena Cava Filter Retrieval in the Medicare Population. Journal of Vascular and Interventional Radiology, 2021, 32, 1164-1169.	0.2	1
165	Should All Coronary Angiographies Be Accompanied by a Renal Arteriogram (and Stent)?. Journal of Clinical Hypertension, 2004, 6, 513-515.	1.0	0
166	Turf Wars: What Certification Brings to the Public and the Physician. The American Heart Hospital Journal, 2005, 3, 277-278.	0.2	0
167	Does balloon angioplasty improve quality of life in patients with hypertension and renal artery stenosis?. Nature Clinical Practice Nephrology, 2006, 2, 18-19.	2.0	0
168	The Massachusetts General Hospital Vascular Center: Emergence of a Multidisciplinary Program Designed to Improve Quality Outcomes for Patients. Hospital Practice (1995), 2009, 37, 22-32.	0.5	0
169	Response to Letter by Altieri et al. Stroke, 2009, 40, .	1.0	0
170	Response to Letters Regarding Article, "Supervised Exercise Versus Primary Stenting for Claudication Resulting From Aortoiliac Peripheral Artery Disease: Six-Month Outcomes From the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) Study― Circulation, 2012, 126, .	1.6	0
171	PAD Is No Longer Related to Rodney. Journal of the American College of Cardiology, 2014, 63, 691-692.	1.2	0
172	The THUNDER Trial Results. JACC: Cardiovascular Interventions, 2015, 8, 109-110.	1.1	0
173	Response to Letter Regarding Article, " ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Enables the Detection of Recurrent Same-Site Deep Vein Thrombosis by Illuminating Recently Formed, Neutrophil-Rich Thrombusâ€r Circulation, 2015, 131, e531-2.	1.6	0
174	How to Treat Critical Limb Ischemia. JACC: Cardiovascular Interventions, 2016, 9, 2566-2567.	1.1	0
175	Can Inferior Vena Cava Filters Change Their Struts?. JACC: Cardiovascular Interventions, 2016, 9, 2449-2451.	1.1	0
176	The Italian stallions of <scp>CLI</scp> "value care―delivery. Catheterization and Cardiovascular Interventions, 2017, 89, 921-922.	0.7	0
177	Stent Versus Scalpel in PeripheralÂArteryÂDisease. JACC: Cardiovascular Interventions, 2017, 10, 2332-2333.	1.1	0
178	Peripheral artery disease: breakthroughs in techniques and treatments. Journal of Cardiovascular Surgery, 2017, 58, 689.	0.3	0
179	Response to Gwozdz and colleagues. Vascular Medicine, 2020, 25, 90-91.	0.8	0
180	Case 30-2021: A 47-Year-Old Man with Recurrent Unilateral Head and Neck Pain. New England Journal of Medicine, 2021, 385, 1317-1325.	13.9	0

0

#	Article	IF	CITATIONS
181	Superficial Thrombophlebitis. , 0, , 80-81.		0
182	Maffucci's Syndrome. , 0, , 174-175.		0
183	Lipedema. , 0, , 96-97.		0
184	Klippel-Trenaunay Syndrome. , 0, , 160-161.		0
185	Reticular Veins. , 0, , 76-77.		0
186	Glomus Tumor. , 0, , 168-169.		0
187	Necrobiosis Lipoidica Diabeticorum. , 0, , 120-121.		0
188	Sickle Cell Induced Leg Ulceration. , 0, , 124-125.		0
189	Milroy's Disease. , 0, , 88-89.		0
190	Onychomycosis (Dermatophytic Onychomycosis). , 0, , 186-187.		0
191	Limb Ulceration Due to Malignant Melanoma. , 0, , 180-181.		0
192	Thalassemia Intermedia Induced Limb Ulceration. , 0, , 126-127.		0
193	Livedo Racemosa. , 0, , 40-41.		0
194	Telangiectasias. , 0, , 74-75.		0
195	Lymphatic Malformations. , 0, , 162-163.		0
196	Post-Traumatic Compartment Syndrome. , 0, , 26-27.		0
197	Ergotism. , 0, , 42-43.		0

198 Elephantiasis Nostras Verrucosa. , 0, , 94-95.

#	Article	IF	CITATIONS
199	Hemangioma of Infancy. , 0, , 164-165.		0
200	Popliteal Cyst (Baker's Cyst). , 0, , 100-101.		0
201	Osler-Weber-Rendu Syndrome. , 0, , 176-177.		0
202	Trench Foot. , 0, , 140-141.		0
203	Gastrocnemius Muscle Rupture. , 0, , 104-105.		0
204	Yellow Nail Syndrome. , 0, , 92-93.		0
205	Frostbite. , 0, , 136-137.		0
206	Renal artery stenosis. Introduction. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2005, 23, S1-3.	0.1	0
207	Renal artery stenosis. Conclusions. Journal of Hypertension Supplement: Official Journal of the International Society of Hypertension, 2005, 23, S31-3.	0.1	0
208	Objective Outcome Measures for Trials in Patients With Chronic Limb-Threatening Ischemia Across 2 Decades. JACC: Cardiovascular Interventions, 2021, 14, 2584-2597.	1.1	0